23andMe Holding Overview
Get informed when a big investor buys or sells
+ Follow-721.75%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
23andMe Holding posts a ROE of -721.75%. That is below the Healthcare sector average of 13.26%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 13.26% is typical. 23andMe Holding's -721.75% is lower that level. That is roughly 5541.8% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
23andMe Holding's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -721.75%; use YoY and peer views to separate noise from signal.
Context for ME's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.26%), and (3) consistency with growth and profitability. This page covers the first two; 23andMe Holding's other metric pages and overview cover the third.
Judging 23andMe Holding against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -721.75% here, then scan peer and history charts to see if the gap is persistent.
